Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance

International Journal of Obesity

Volumn 28, Issue , 2004, Pages S45-S52

  Asensio, C ^a,b   Muzzin, P ^b   Rohner Jeanrenaud, F ^a  

^a Faculty of Medicine   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Glucocorticoids; Glucose metabolism; Insulin sensitivity; Melanocortin system; Neuropeptide y; Resistin

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; GLUCOSE; MELANOCORTIN; MELANOCORTIN AGONIST; NEUROPEPTIDE Y; RESISTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARCUATE NUCLEUS; BODY WEIGHT; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENERGY BALANCE; FOOD INTAKE; GENE OVEREXPRESSION; GLUCOSE METABOLISM; HOMEOSTASIS; HORMONAL REGULATION; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERPHAGIA; INSULIN RESISTANCE; LIPID OXIDATION; LIPID STORAGE; METABOLIC DISORDER; MOUSE; NONHUMAN; PARASYMPATHETIC NERVE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEROID METABOLISM; VAGOTOMY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ALPHA-MSH; ANIMALS; CENTRAL NERVOUS SYSTEM; DEXAMETHASONE; GLUCOCORTICOIDS; GLUCOSE; HOMEOSTASIS; HORMONES, ECTOPIC; HUMANS; INSULIN; INSULIN RESISTANCE; MICE; NEUROPEPTIDE Y; RATS; RESISTIN;

ANIMALIA;

EID: 12444257790     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802856     Document Type: Article

References (91)

1. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671.
2. Rohner-Jeanrenaud F. Aspects of the neuroendocrine regulation of body weight homeostasis. Ann Endocrinol (Paris) 2002; 63: 125-128.
3. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol 2003; 24: 1-10.
4. Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002; 440: 235-254.
5. Plotsky PM, Thrivikraman KV, Watts AG, Hauger RL. Hypothalamic- pituitary-adrenal axis function in the Zucker obese rat. Endocrinology 1992; 130: 1931-1941.
6. Walker CD, Scribner KA, Stern JS, Dallman MF. Obese Zucker (fa/fa) rats exhibit normal target sensitivity to corticosterone and increased drive to adrenocorticotropin during the diurnal trough. Endocrinology 1992; 131: 2629-2637.
7. Pacak K, McCarty R, Palkovits M, Cizza G, Kopin IJ, Goldstein DS, Chrousos GP. Decreased central and peripheral catecholaminergic activation in obese Zucker rats. Endocrinology 1995; 136: 4360-4367.
8. Havel PJ, Busch BL, Curry DL, Johnson PR, Dallman MF, Stern JS. Predominately glucocorticoid agonist actions of RU-486 in young specific-pathogen-free Zucker rats. Am J Physiol 1996; 271: R710-R717.
9. Richard D, Rivest R, Naimi N, Timofeeva E, Rivest S. Expression of corticotropin-releasing factor and its receptors in the brain of lean and obese Zucker rats. Endocrinology 1996; 137: 4786-4795.
10. Timofeeva E, Richard D. Functional activation of CRH neurons and expression of the genes encoding CRH and its receptors in food-deprived lean (Fa/?) and obese (fa/fa) Zucker rats. Neuroendocrinology 1997; 66: 327-340.
11. Timofeeva E, Deshaies Y, Picard F, Richard D. Corticotropinreleasing hormone-binding protein in brain and pituitary of food-deprived obese (fa/fa) Zucker rats. Am J Physiol 1999; 277: R1749-R1759.
12. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000; 141: 560-563.
13. Livingstone DE, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 2000; 167: 533-539.
14. Cunningham JJ, Calles-Escandon J, Garrido F, Carr DB, Bode HH. Hypercorticosteronuria and diminished pituitary responsiveness to corticotropin-releasing factor in obese Zucker rats. Endocrinology 1986; 118: 98-101.
15. White BD, Corll CB, Porter JR. The metabolic clearance rate of corticosterone in lean and obese male Zucker rats. Metabolism 1989; 38: 530-536.
16. Mattsson C, Lai M, Noble J, McKinney E, Yau JL, Seckl JR, Walker BR. Obese Zucker rats have reduced mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 1 expression in hippocampus-implications for dysregulation of the hypothalamic- pituitary-adrenal axis in obesity. Endocrinology 2003; 144: 2997-3003.
17. Andrew R, Phillips DI, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998; 83: 1806-1809.
18. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999; 33: 1364-1368.
19. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisonecortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999; 84: 1022-1027.
20. Pasquali R, Gagliardi L, Vicennati V, Gambineri A, Colitta D, Ceroni L, Casimirri F. ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. Int J Obes Relat Metab Disord 1999; 23: 419-424.
21. Pasquali R, Vicennati V, Calzoni F, Gnudi U, Gambineri A, Ceroni L, Cortelli P, Menozzi R, Sinisi R, Rio GD. alpha2-adrenoceptor regulation of the hypothalamic-pituitary-adrenocortical axis in obesity. Clin Endocrinol (Oxford) 2000; 52: 413-421.
22. Marin P, Darin N, Amemiya T, Andersson B, Jern S, Bjorntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992; 41: 882-886.
23. Hautanen A, Adlercreutz H. Altered adrenocorticotropin and cortisol secretion in abdominal obesity: implications for the insulin resistance syndrome. J Intern Med 1993; 234: 461-469.
24. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853-1859.
25. Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res 1996; 4: 277-282.
26. Jessop DS, Dallman MF, Fleming D, Lightman SL. Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 2001; 86: 4109-4114.
27. Di Blasio AM, van Rossum EF, Maestrini S, Berselli ME, Tagliaferri M, Podesta F, Koper JW, Liuzzi A, Lamberts SW. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin Endocrinol (Oxford) 2003; 59: 68-74.
28. Reynolds RM, Chapman KE, Seckl JR, Walker BR, McKeigue PM, Lithell HO. Skeletal muscle glucocorticoid receptor density and insulin resistance. JAMA 2002; 287: 2505-2506.
29. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002; 51: 1066-1075.
30. Shimomura Y, Bray GA, Lee M. Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res 1987; 19: 295-299.
31. Zakrzewska KE, Cusin I, Stricker-Krongrad A, Boss O, Ricquier D, Jeanrenaud B, Rohner-Jeanrenaud F. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 1999; 48: 365-370.
32. Cusin I, Rouru J, Rohner-Jeanrenaud F. Intracerebroventricular glucocorticoid infusion in normal rats: induction of parasympathetic- mediated obesity and insulin resistance. Obes Res 2001; 9: 401-406.
33. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-1758.
34. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle. Diabetes 1994; 43: 764-769.
35. Sainsbury A, Rohner-Jeanrenaud F, Grouzmann E, Jeanrenaud B. Acute intracerebroventricular administration of neuropeptide Y stimulates corticosterone output and feeding but not insulin output in normal rats. Neuroendocrinology 1996; 63: 318-326.
36. Sainsbury A, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B. Adrenalectomy prevents the obesity syndrome produced by chronic central neuropeptide Y infusion in normal rats. Diabetes 1997; 46: 209-214.
37. Zakrzewska KE, Sainsbury A, Cusin I, Rouru J, Jeanrenaud B, Rohner-Jeanrenaud F. Selective dependence of intracerebroventricular neuropeptide Y-elicited effects on central glucocorticoids. Endocrinology 1999; 140: 3183-3187.
38. Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004; 59: 359-393.
39. Moisan MP, Seckl JR, Edwards CR. 11 beta-hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology 1990; 127: 1450-1455.
40. Lakshmi V, Sakai RR, McEwen BS, Monder C. Regional distribution of 11 beta-hydroxysteroid dehydrogenase in rat brain. Endocrinology 1991; 128: 1741-1748.
41. Seckl JR, Dow RC, Low SC, Edwards CR, Fink G. The 11 betahydroxysteroid dehydrogenase inhibitor glycyrrhetinic acid affects corticosteroid feedback regulation of hypothalamic corticotrophin- releasing peptides in rats. J Endocrinol 1993; 136: 471-477.
42. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105: R11-R17.
43. Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CR, Seckl JR. Cloning and production of antisera to human placental 11 betahydroxysteroid dehydrogenase type 2. Biochem J 1996; 313 (Part 3): 1007-1017.
44. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997; 94: 14924-14929.
45. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
46. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112: 83-90.
47. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-1421.
48. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002; 87: 3330-3336.
49. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-2705.
50. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, Tataranni PA, Walker BR. Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003; 88: 2738-2744.
51. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, Walker BR. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 2003; 88: 3983-3988.
52. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, Hakkinen AM, Andrew R, Wake DJ, Seckl JR, Walker BR. Body fat distribution and cortisol metabolism in healthy men: enhanced 5betareductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 2003; 88: 4924-4931.
53. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
54. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
55. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192.
56. Reginato MJ, Lazar MA. Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 1999; 10: 9-13.
57. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissuespecific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276: 11252-11256.
58. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale Jr FV, Shelton DL, Hebert CC. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000; 19: 4046-4055.
59. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98: 502-506.
60. Morash BA, Willkinson D, Ur E, Wilkinson M. Resistin expression and regulation in mouse pituitary. FEBS Lett 2002; 526: 26-30.
61. Nogueiras R, Gallego R, Gualillo O, Caminos JE, Garcia-Caballero T, Casanueva FF, Dieguez C. Resistin is expressed in different rat tissues and is regulated in a tissue- and gender-specific manner. FEBS Lett 2003; 548: 21-27.
62. Haugen F, Jorgensen A, Drevon CA, Trayhurn P. Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 105-108.
63. Del Arco A, Peralta S, Carrascosa JM, Ros M, Andres A, Arribas C. Alternative splicing generates a novel non-secretable resistin isoform in Wistar rats. FEBS Lett 2003; 555: 243-249.
64. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225-230.
65. Pravenec M, Kazdova L, Landa V, Zidek V, Mlejnek P, Jansa P, Wang J, Qi N, Kurtz TW. Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J Biol Chem 2003; 278: 45209-45215.
66. Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003; 285: E106-E115.
67. Yang RZ, Huang Q, Xu A, McLenithan JC, Eison JA, Shuldiner AR, Alkan S, Gong DW. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003; 310: 927-935.
68. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286-290.
69. Raghu P, Ghosh S, Soundarya K, Haseeb A, Aruna B, Ehtesham NZ. Dimerization of human recombinant resistin involves covalent and noncovalent interactions. Biochem Biophys Res Commun 2004; 313: 642-646.
70. Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C, Harlan DM, Shalev A. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 2003; 310: 641-645.
71. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202.
72. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561-564.
73. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002; 10: 1-5.
74. Seow KM, Juan CC, Wu LY, Hsu YP, Yang WM, Tsai YL, Hwang JL, Ho LT. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod 2004; 19: 48-53.
75. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455.
76. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
77. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK, Park KS. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 150-156.
78. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003; 88: 6098-6106.
79. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003; 149: 331-335.
80. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003; 52: 1611-1618.
81. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-47.
82. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002; 87: 2407.
83. Asensio C, Cettour-Rose P, Theander-Carrillo C, Rohner-Jeanrenaud F, Muzzin P. Changes of glycemia by leptin administration or high fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis. Endocrinology 2004; 145: 2206-2213.
84. Ellacott KL, Cone RD. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Prog Horm Res 2004; 59: 395-408.
85. Cettour-Rose P, Rohner-Jeanrenaud F. The leptin-like effects of 3- d peripheral administration of a melanocortin agonist are more marked in genetically obese Zucker (fa/fa) than in lean rats. Endocrinology 2002; 143: 2277-2283.
86. Harrold JA, Widdowson PS, Williams G. Altered energy balance causes selective changes in melanocortin-4(MC4-R), but not melanocortin-3 (MC3-R), receptors in specific hypothalamic regions: further evidence that activation of MC4-R is a physiological inhibitor of feeding. Diabetes 1999; 48: 267-271.
87. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999; 5: 1066-1070.
88. Li G, Mobbs CV, Scarpace PJ. Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes 2003; 52: 1951-1957.
89. Vettor R, Zarjevski N, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B. Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 1994; 37: 1202-1208.
90. Sainsbury A, Cusin I, Doyle P, Rohner-Jeanrenaud F, Jeanrenaud B. Intracerebroventricular administration of neuropeptide Y to normal rats increases obese gene expression in white adipose tissue. Diabetologia 1996; 39: 353-356.
91. Sainsbury A, Rohner-Jeanrenaud F, Cusin I, Zakrzewska KE, Halban PA, Gaillard RC, Jeanrenaud B. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamopituitary- adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997; 40: 1269-1277.